Results 171 to 180 of about 41,598 (251)

Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Forty‐three HS specialists from 22 European countries reported adherence to HS guidelines and use of antibiotics before biologics despite limited efficacy and rapid relapse (49% within 1–3 months). Seventy‐nine per cent supported short‐term biologics for severe Hurley I disease.
Georgios Nikolakis, Erkan Alpsoy, Monika Arenbergerova, Falk G. Bechara, Farida Benhadou, Joana Cabete, Raffaele Dante Caposiena Caro, Giovanni Damiani, Maia Delage Toriel, Veronique Del Marmol, Valentina Dini, Evangelos J. Giamarellos‐Bourboulis, Katalin Glasenhardt, Philippe Guillem, Ariela Hafner, Evgeniya Hristakieva, John R. Ingram, Vaiva Jarienè, Gregor B. E. Jemec, Niamh Kearney, Brian Kirby, Natalia Kirsten, Piotr K. Krajewski, Vesta Kucinskiene, Aikaterini I. Liakou, Flavia Manzo Margiotta, Angelo V. Marzano, Antonio Martorell, Lukasz Matusiak, Dillon Mintoff, Alejandro Molina Leyva, Francesca Prignano, Tadas Raudonis, Hans Christian Ring, Marco Romanelli, Samed Şahin, Ditte M. L. Saunte, Linnea Thorlacius, Thrasyvoulos Tzellos, Hessel H. Van Der Zee, Kelsey Van Straalen, Christos C. Zouboulis   +41 more
wiley   +1 more source

IgA Deficiency and Nephrotic Syndrome in Children. [PDF]

Int J Environ Res Public Health, 2018
Di Genova L, Ceppi S, Stefanelli M, Esposito S.   +3 more
europepmc   +1 more source

Long‐term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236‐week, Phase 3 trial results

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase III study, secukinumab demonstrated sustained efficacy and a favourable safety profile in paediatric patients with chronic severe plaque psoriasis over a treatment period of 236 weeks. Abstract Background Plaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population.
Andrzej Kaszuba, Philemon Papanastasiou, Dorota Krasowska, Raul De Lucas Laguna, Michael Ziv, Shoba Ravichandran, Amita Bansal, Swapnil S. Dahale, Ruvie Martin, Bertrand Paguet, Nina Magnolo, Kulli Kingo   +11 more
wiley   +1 more source

Efficacy of up to 4 years of tralokinumab in adults with moderate‐to‐severe atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
AD is a relapsing and remitting skin disease often requiring long‐term treatment. We assessed the long‐term efficacy of tralokinumab in adults with moderate‐to‐severe AD consistently treated for up to 4 years. Treatment with tralokinumab plus optional TCS/TCI provided substantial improvements in AD signs and symptoms, and these improvements were ...
Melinda Gooderham, Mahreen Ameen, H. Chih‐ho Hong, Norito Katoh, Richard G. Langley, Ketty Peris, Kristian Reich, Juan F. Silvestre, Eric Simpson, Thomas Werfel, Le Gjerum, Ann‐Marie Tindberg, Christian Bjerregård Øland, Andrew Blauvelt   +13 more
wiley   +1 more source

Immune/microbial interface perturbation in human IgA deficiency. [PDF]

Gut Microbes, 2019
Sterlin D, Fieschi C, Malphettes M, Larsen M, Gorochov G, Fadlallah J.   +5 more
europepmc   +1 more source

The SWITCH algorithm: An expert consensus on treat‐to‐target criteria for chronic prurigo

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The SWITCH project assessed patients' most distressing symptoms and therapy goals, followed by an expert‐based consensus procedure to define T2T criteria for patients with chronic prurigo (CPG)/prurigo nodularis. Based on these validated criteria, a 4‐step SWITCH algorithm was established to enhance CPG therapy outcomes and reduce patient burden ...
Lea S. Stahl, Claudia Zeidler, Joyce Loewenthal, Svenja Royeck, Matthias Augustin, Robert Bissonnette, Sarina Elmariah, Brian S. Kim, Laurent Misery, Hiroyuki Murota, Hong Liang Tey, Elke Weisshaar, Gil Yosipovitch, Franz J. Legat, Adam Reich, Martin Metz, Sonja Ständer   +16 more
wiley   +1 more source

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Franz J. Legat, Shawn G. Kwatra, Adam Reich, Serge Boulinguez, Athanasios Tsianakas, Maxwell Sauder, Sebastien Barbarot, Jacek C. Szepietowski, Curdin Conrad, Andrew E. Pink, Elke Weisshaar, Laurent Misery, Martin Metz, Vivian T. Laquer, Raja K. Sivamani, Gil Yosipovitch, Diamant Thaçi, Lone Skov, Xiaoxiao Chen, Aliene Noda, Zarif K. Jabbar‐Lopez, Christophe Piketty, Sonja Ständer   +22 more
wiley   +1 more source

Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The results of this French Early Access Program were consistent with those reported in dupilumab randomized clinical trials in children aged 6 months–5 years with moderate‐to‐severe AD. This research offers insights into the practical use of dupilumab in routine clinical practice.
Audrey Lasek, Nathalia Bellon, Stéphanie Mallet, Hélène Aubert, Carine Vera, Lamia Achour, Claire Thénié, Randy Prescilla, Claire Abasq‐Thomas, Sébastien Barbarot   +9 more
wiley   +1 more source

Antibiotic treatment-induced secondary IgA deficiency enhances susceptibility to Pseudomonas aeruginosa pneumonia. [PDF]

J Clin Invest, 2018
Robak OH, Heimesaat MM, Kruglov AA, Prepens S, Ninnemann J, Gutbier B, Reppe K, Hochrein H, Suter M, Kirschning CJ, Marathe V, Buer J, Hornef MW, Schnare M, Schneider P, Witzenrath M, Bereswill S, Steinhoff U, Suttorp N, Sander LE, Chaput C, Opitz B.   +21 more
europepmc   +1 more source

European S2k guidelines on management of autoimmune blistering diseases in children and adolescents

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Autoimmune blistering disorders (AIBDs) in children are rare, challenging to diagnose and treat and often require immunosuppressants. Until now, no paediatric care guidelines existed. The EADV Task Force for AIBDs has developed the consensus‐based recommendations, enabling physicians to adopt a uniform, tailored treatment strategy to improve outcomes ...
A. Nanda, B. Tedbirt, C. Bodemer, M. C. Bolling, M. El Hachem, M. Nikolić, E. Benton, M. Caproni, D. De, D. Didona, K. Drenovska, M. Goebeler, M. Hertl, B. Horváth, M. Kasperkiewicz, D. Kiritsi, M. Larralde, A. V. Marzano, J. Meijer, D. F. Murrell, J. Powell, E. Sprecher, N. S. Chandran, M. M. Tomayko, S. Uzun, N. van Beek, H. Ott, A. Patsatsi, A. Torrelo, A. Welfringer‐Morin, E. Schmidt, P. Joly   +31 more
wiley   +1 more source